I'll verify what this entity actually is before profiling it.
The named party is a qui tam relator, not a company. Let me verify the individual's associated business.
This entry is not a company. "United States ex rel. Leonardo Sorgi" is the caption of a qui tam action under the federal False Claims Act; "ex rel." means a private relator suing on the government's behalf. The individual is Leonardo S. Sorgi, a patent attorney whose practice, per his complaint, "focuses on investigating invalid pharmaceutical patents that brand manufacturers use to protect their drugs from price competition." He also states he is president and founder of Lahti Analytica, Inc., an IP consulting business. That entity does not appear in the case data, and I could not independently verify its details. No headquarters, headcount, revenue, or ticker applies.
Tracked footprint. Our database records exactly one appearance: as relator/plaintiff in United States ex rel. Leonardo Sorgi v. Jazz Pharmaceuticals PLC et al., No. 1:21-cv-10891-PBS (D. Mass.), filed May 27, 2021, before Judge Patti B. Saris. Defendants are Jazz Pharmaceuticals plc (Dublin, Ireland), Jazz Pharmaceuticals, Inc. (Palo Alto, California) and Jazz Pharmaceuticals Ireland Limited.
Litigation posture. Sorgi is neither an operating company defending infringement suits nor a patent-assertion entity; the single case is affirmative FCA enforcement, not a patent infringement claim, so the "1 plaintiff / 0 defendant" split reflects a relator, not a portfolio-asserting NPE. Venue is the District of Massachusetts — not a plaintiff-friendly patent venue such as the Eastern District of Texas.
Allegations and outcome. The complaint alleged Jazz fraudulently procured patents on Xyrem (sodium oxybate) — the '306 patent family covering coadministration with CNS depressants such as valproate — by withholding material prior art, blocking generics and causing inflated Medicare/Medicaid reimbursement. The federal and state governments declined to intervene. On September 23, 2025, the court dismissed the action under the FCA's public disclosure bar, holding that ex parte patent prosecution dockets qualify as public disclosures and that Sorgi, lacking insider knowledge, was not an original source (Bloomberg Law; VitalLaw; Docket No. 103). A related state-law parallel, New York et al. v. Jazz Pharmaceuticals (1:25-cv-08797), lists Sorgi as a plaintiff; it falls outside our tracked data.